Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Or leave a message with a formal purchase order (PO) Or credit card.
OPG-Fc Fusion Protein
Conditions of optimal OPG Protein performance should be determined experimentally by the investigator.
Osteoprotegerin (OPG) also known as Osteoclast Inhibiting Factor (OCIF) or Osteoclast Binding Factor (OBF), is a key factor inhibiting the differentiation and activation of osteoclasts, and is therefore essential for bone resorption. Osteoprotegerin is a glycoprotein belonging to the TNF receptor family. As a so called soluble "decoy" receptor, Osteoprotegerin inhibits the binding of RANK to RANKL and thus inhibits the recruitment, proliferation and activation of osteoclasts.
BP000051-GD14: Recombinant Human OPG-Fc Fusion Protein
Source: HEK 293-derived.
The Osteoprotegerin / OPG / TNFRSF11B / OCIF / OBF activity is calculated by its ability to inhibit TRAIL-mediated cytotoxicity using L929 mouse fibrosarcoma cells treated with TRAIL. The ED50 for this effect is typically 5 ng/ml.
Endotoxin: < 5.0 EU per 1 ug of the protein by the LAL method.
Purity: > 90% by SDS-PAGE and RP-HPLC.
Formulation: In 1% Surcose, 100 mM NaCl, 25 mM L-arginine hydrochloride, and 25 mM sodium phosphate. pH 6.3.
Shipping: The product is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution.